Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Inclusion Criteria:

• Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solidtumors who have received standard of care or are intolerant or ineligible toapproved therapies

• ECOG Performance Status of 0 or 1

• At least one measurable lesion as defined by RECIST 1.1

• Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations ofcombinations and a subset of groups in dose expansion

Exclusion Criteria:

• Tumors harboring driver mutations that have approved targeted therapies, with theexception of KRAS G12C mutations

• Symptomatic brain metastases or known leptomeningeal disease. Patients withasymptomatic treated or untreated brain metastases may be eligible

• Clinically significant cardiac disease or risk factors at screening

• A medical condition that results in increased photosensitivity Otherprotocol-defined inclusion/exclusion criteria may apply.